Nuvation Bio

ROS1 Lung Cancer Leadership And Glioma Opportunity Will Transform Long Term Oncology Impact

AnalystHighTarget

Not Invested

Community Contributor

Published

21 Dec 25

Views

n/a

AnalystHighTarget's Fair Value

n/a

252.2%

12.0%

252.2%

12.0%

You can edit this narrative until Dec 22 3:07 AM. Then, changes will post as Updates.

Author's Valuation

US$16.843.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$16.8

43.8% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

48.70%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$38.02m

Earnings '28

192.18x

PE Ratio '28

US$7.31b

Market Cap '28

US$7.31b

Market Cap '28

355.61m

No. shares '28

US$20.55

Share Price '28

US$20.55 Share Price '28

Discounted to 2025 @ 6.96% p.a.

US$16.80

Fair Value '25